Market Cap : 339.06 M | Enterprise Value : 36.96 M | PE Ratio : At Loss | PB Ratio : 1.51 |
---|
NAS:ATRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ATRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2022-08-09), Atara Biotherapeutics's share price is $3.63. Atara Biotherapeutics's Book Value per Share for the quarter that ended in Mar. 2022 was $2.40. Hence, Atara Biotherapeutics's PB Ratio of today is 1.51.
The historical rank and industry rank for Atara Biotherapeutics's PB Ratio or its related term are showing as below:
During the past 10 years, Atara Biotherapeutics's highest PB Ratio was 5.68. The lowest was 1.26. And the median was 3.62.
ATRA's PB Ratio is ranked better thanDuring the past 12 months, Atara Biotherapeutics's average Book Value Per Share Growth Rate was -49.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -25.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -15.20% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Atara Biotherapeutics was 3.40% per year. The lowest was -25.50% per year. And the median was -12.70% per year.
The historical data trend for Atara Biotherapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Atara Biotherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Atara Biotherapeutics's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Mar. 2022) |
= | 3.63 | / | 2.402 | |
= | 1.51 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Atara Biotherapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Yarema Kristin | officer: Chief Commercial Officer | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Murugan Amar | officer: SVP, GC & Secretary | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD,SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Dupont Jakob | officer: EVP, Head of R&D | C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 |
Touchon Pascal | director, officer: President and CEO | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Koppikar Utpal | officer: Chief Financial Officer | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Mallik Ameet | director | C/O RAFAEL HOLDINGS, INC. 520 BROAD ST NEWARK NJ 07102 |
Renaud Ronald C Jr | director | C/O IDENIX PHARMACEUTICALS, INC. 60 HAMPSHIRE STREET CAMBRIDGE MA 02109 |
Seidenberg Beth C | director | |
Heiden William K | director | C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451 |
Dobmeier Eric | director | C/O SAETTLE GENETICS INC 21823 30TH DRIVE SE BOTHELL WA 98021 |
Roncarolo Maria Grazia | director | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Gallagher Carol Giltner | director | C/O ATARA BIOTHERAPEUTICS, INC. 3260 BAYSHORE BOULEVARD BRISBANE CA 94005 |
Fust Matthew K | director | C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949 |
Baynes Roy D. | director | C/O RETROPHIN, INC. 12255 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130 |
Berger Dietmar | officer: Global Head of R&D | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Other Sources
By Seekingalpha 2021-09-20
By tipranks.com 2022-02-28
By Zacks 2021-05-04
By Zacks 2021-08-09
By Zacks 2021-01-26
By tipranks.com 2022-04-04
By Zacks 2021-11-04